With this application the Toledo Community Clinical Oncology Program (TCCOP) seeks funding for the continuation of its ongoing clinical trials and cancer control research activities. In this application TCCOP will present a track record in clinical trials research and a proven capability in cancer control research which will provide a firm basis for continuation of our program. In cooperation with the Medical College of Ohio we will continue clinical trials research with the Eastern Cooperative Oncology Group (ECOG) as our research base. With ECOG and with the Ohio State University Comprehensive Cancer Center as an additional base we will undertake a new series of cancer control research projects. The cancer control activities of TCCOP will be further strengthened during the period of this grant by relocation of TCCOP operations into the offices of the Toledo Community Hospital Oncology Program, an ongoing cancer control program in this community originally funded by the National Cancer Institute. To augment our program three new components who have previous experience in clinical trials and an interest in cancer control research will be added to TCCOP. Physician and allied health professionals will continue to contribute to the scientific activities of ECOG by attendance at the group meetings and by service on several standing committees. TCCOP will also continue to encourage and support community wide educational programs and workshops to bring state-of-the-art cancer medicine to the attention of cancer care providers and to encourage referral of patients for clinical trials research.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Cooperative Clinical Research--Cooperative Agreements (U10)
Project #
2U10CA035415-04
Application #
3557743
Study Section
(SRC)
Project Start
1983-09-15
Project End
1990-05-31
Budget Start
1987-08-25
Budget End
1988-05-31
Support Year
4
Fiscal Year
1987
Total Cost
Indirect Cost
Name
Toledo Community Hospital Oncology Prog
Department
Type
DUNS #
City
Toledo
State
OH
Country
United States
Zip Code
43617
Barton, Debra L; Sloan, Jeff A; Shuster, Lynne T et al. (2018) Evaluating the efficacy of vaginal dehydroepiandosterone for vaginal symptoms in postmenopausal cancer survivors: NCCTG N10C1 (Alliance). Support Care Cancer 26:643-650
Schild, Steven E; Hillman, Shauna L; Tan, Angelina D et al. (2017) Long-Term Results of a Trial of Concurrent Chemotherapy and Escalating Doses of Radiation for Unresectable Non-Small Cell Lung Cancer: NCCTG N0028 (Alliance). J Thorac Oncol 12:697-703
Liu, Xiaonan; Li, Jing; Schild, Steven E et al. (2017) Statins and Metformin Use Is Associated with Lower PSA Levels in Prostate Cancer Patients Presenting for Radiation Therapy. J Cancer Ther 8:73-85
Sio, Terence T; Atherton, Pamela J; Birckhead, Brandon J et al. (2016) Repeated measures analyses of dermatitis symptom evolution in breast cancer patients receiving radiotherapy in a phase 3 randomized trial of mometasone furoate vs placebo (N06C4 [alliance]). Support Care Cancer 24:3847-55
Tan, A D; Novotny, P J; Kaur, J S et al. (2016) QOL and Survival Comparisons by Race in Oncology Clinical Trials. J Cancer Clin Oncol 2:
Liu, Xiaonan; Li, Jing; Wu, Teresa et al. (2016) Patient Specific Characteristics Are an Important Factor That Determines the Risk of Acute Grade ? 2 Rectal Toxicity in Patients Treated for Prostate Cancer with IMRT and Daily Image Guidance Based on Implanted Gold Markers. OMICS J Radiol 5:
Pachman, Deirdre R; Qin, Rui; Seisler, Drew et al. (2016) Comparison of oxaliplatin and paclitaxel-induced neuropathy (Alliance A151505). Support Care Cancer 24:5059-5068
Liu, Heshan; Tan, Angelina D; Qin, Rui et al. (2015) Comparing and Validating Simple Measures of Patient-Reported Peripheral Neuropathy for Oncology Clinical Trials: NCCTG N0897 (Alliance) A Pooled Analysis of 2440 Patients. SOJ Anesthesiol Pain Manag 2:
Wagner-Johnston, Nina D; Sloan, Jeff A; Liu, Heshan et al. (2015) 5-year follow-up of a randomized controlled trial of immediate versus delayed zoledronic acid for the prevention of bone loss in postmenopausal women with breast cancer starting letrozole after tamoxifen: N03CC (Alliance) trial. Cancer 121:2537-43
Dueck, A C; Singh, J; Atherton, P et al. (2015) Endpoint comparison for bone mineral density measurements in North Central Cancer Treatment Group cancer clinical trials N02C1 and N03CC (Alliance). Osteoporos Int 26:1971-7

Showing the most recent 10 out of 130 publications